Expression of the protein-coding gene hnRNP K is significantly reduced in AML patients who carry a specific genetic deletion.

Sean Post, assistant professor at The University of Texas MD Anderson Cancer Center in the US, said, "Our data implicates hnRNP K in the development of blood disorders and suggests it acts as a tumor suppressor. Both in vivo and in vitro results indicate that hnRNP K achieves this through regulation of key genetic pathways. Our study found that hnRNP K expression must be maintained for proper cellular regulation and to prevent tumor formation."
The study was published in Cancer Cell.
Source-IANS
MEDINDIA



Email










